Indivior Pharmaceuticals, Inc.
INDV· Nasdaq
INDVIndivior Pharmaceuticals, Inc.
Filed Oct 30, 2025 · 10-Q · 30 days after period end · 0001628280-25-047530
| Metric | Q3 2025 | Q3 2024 |
|---|---|---|
| Revenue | $314.00M | $307.00M |
| Net Income | $42.00M | $22.00M |
| EPS Diluted | $0.33 | $0.16 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Indivior Pharmaceuticals, Inc. · CIK 1625297 · Engraved from SEC EDGAR
ended Sep 30, 2025 · filed Oct 30, 2025 · 30 d after period end
